Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its product candidates ...

Merck agreed to buy Acceleron Pharma Thursday in a deal that values the rare drug specialists at around $11.5 billion. Merck will pay $180 per share for Cambridge, Massachusetts-based Acceleron ...

After days of speculation, Merck & Co confirmed today that it has agreed to acquire Acceleron Pharma $1.5 billion, setting up what could be one of the largest biopharma acquisitions of 2021 so far.

Shares in Acceleron have been grown by the third in the last month, and closed on Friday at almost $168, not far off its 52-week high of $174. Image Phil Taylor ...

We believe that the pharmaceuticals bellwether Johnson & Johnson (NYSE: JNJ) is currently a better pick over its peer Merck ...

One analyst thinks the collaboration “bodes well” for Gossamer, which has had trouble convincing investors its drug seralutinib can compete on the market.

The Italian pharma will gain access to Gossamer Bio’s candidate seralutinib, which reached its primary endpoint in a Phase II ...

Italian pharma Chiesi is betting almost $500 million on Gossamer Bio's pulmonary arterial hypertension (PAH) candidate.  | ...

The company acquired Winrevair, also known by the generic name sotatercept, through an $11.5 billion acquisition of the ...

At the time of its Acceleron buyout, the company projected Winrevair, also known as sotatercept, would compete in a PAH drug ...

Four months into Davis’ tenure as CEO in 2021, the company acquired sotatercept in an $11.5 billion buyout of Acceleron. Data analytics group FactSet has projected sales of Winrevair to reach $3 ...

Acceleron Pharma, Inc. is a public American "clinical stage biopharmaceutical company" based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming ...